Turkiye Klinikleri Cardiovascular Sciences

.: REVIEW
Türk Toplumunda Yüksek Kardiyovasküler Riskli Hastalarda LDL-Kolesterol Düzeylerinin Değerlendirildiği Sistematik Derleme
A Systematic Evaluation of LDL-Cholesterol Levels of High Cardioovascular Risk Patients in Turkish Population
Pınar KIZILIRMAKa, Zeki ÖNGENb, Meral KAYIKÇIOĞLUc, Lale TOKGÖZOĞLUd
aAMGEN, Medikal Bölüm,
bKardiyoloji ABD, İstanbul Üniversitesi-Cerrahpaşa Cerrahpaşa Tıp Fakültesi, İstanbul, TÜRKİYE
cKardiyoloji ABD, Ege Üniversitesi Tıp Fakültesi,
dKardiyoloji ABD, Hacettepe Üniversitesi Tıp Fakültesi, Ankara, TÜRKİYE
Turkiye Klinikleri J Cardiovasc Sci. 2019;31(3):162-93
doi: 10.5336/cardiosci.2019-70392
Article Language: TR
Full Text
ÖZET
 Amaç: Türkiye'de yapılmış veya yayımlanmış makalelerin verilerini değerlendirerek Türk toplumunda kardiyovasküler riski yüksek olan hastalarda düşük dansiteli lipoprotein (LDL)-kolesterol düzeylerini ortaya koymaktır. Gereç ve Yöntemler: 1 Ocak 2008-31 Aralık 2017 tarihleri arasında yayımlanmış ve başlık veya özetinde LDL* ve TURK* terimlerini içeren yayınlar arasında, popülasyonunda kardiyovasküler hastalık (KVH), diabetes mellitus (DM) veya hipertansiyon olan ve bireylere ait ortalama LDL-kolesterol değeri içeren tam metin şeklindeki yayınlar çalışmaya dâhil edildi. Verilerin tanımlayıcı istatistiksel analizi yapıldı. Verilerin "hasta sayısına göre ağırlıklandırılmış ortalama değerleri" hesaplandı. Bulgular: Yüz elli yedi çalışmada yer alan toplam 35.855 hastanın ve 5.918 KVH olmayan bireyin verileri değerlendirildi KVH, DM ve hipertansiyon popülasyonlarında ortalama LDL-kolesterol düzeyleri sırasıyla 119,8±36,6 mg/dL, 124,2±36,4 mg/dL ve124,3±36,9 mg/dL'dir. KVH popülasyonunun %90,4'ünde, DM popülasyonunun %92,5'inde, hipertansiyon popülasyonunun %92,8'inde ve KVH olmayan bireylerin %91,4'ünde LDL-kolesterol 70 mg/dL'nin üzerindedir. Sonuç: KVH, DM ve hipertansiyonu olan toplam 35.855 hastanın büyük çoğunluğunda LDL-kolesterol ≤70 mg/dL hedeflenen düzeyinde değildir. Bu durum, prevalansı yüksek olan bu hastalıkların kontrolünü yetersiz kılarak ülkeye ciddi bir ekonomik yükü beraberinde getirmesi açısından önemlidir.

Anahtar Kelimeler: Diabetes mellitus; hipertansiyon; kardiyovaskuler hastalık; LDL-kolesterol; Türkiye
ABSTRACT
 Objective: To present the findings related with the low lipoprotein (LDL)- cholesterol levels of high cardiovascular risk patients in Turkish population by evaluating the data of articles performed and published in Turkey. Material and Methods: Among the articles including LDL* and TURK* in the title or abstract and published between 2008, January 1-2017, December 31, the full text articles on cardiovascular disease (CVD), diabetes mellitus (DM) or hypertension populations and with mean LDL cholesterol data of patients were included. The data were analyzed using the descriptive statistics. "The weighted mean of data considering patient numbers" were calculated. Results: The data of a total of 35.855 patients and 5.918 non-CVD subjects in 157 studies were evaluated. In CVD, DM and hypertension populations, the mean LDL-cholesterol levels were 119.8±36.6 mg/dL, 124.2±36.4 mg/dL, and 124.3±36.9 mg/dL, respectively. The LDL-cholesterol was higher than 70 mg/dL in 90.4% of CVD population, 92.5% of DM population, 92.8% of hypertension population and 91.4% of non-CVD subjects. Conclusion: In the majority of a total of 35.855 patients with CVD, DM and hypertension, the LDL-cholesterol was not in target levels of ≤70 mg/dL. This finding is important as it causes inadequate control of these diseases with high prevalence and is a high economic burden in the country.

Keywords: Diabetes mellitus; hypertension; cardiovascular disease; LDL-cholesterol; Turkey
REFERENCES:
  1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al; ESC Scientific Document Group. Authors/task force members: additional contributer. 2016 ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2017;37(39):2999-3058. [Crossref]  [PubMed] 
  2. Elisaf M, Pitsavos C, Liberopoulos E, Tziomalos K, Athyros VG. Updated Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia-2014. Hellenic J Atheroscler. 2014;5(3):151-63.
  3. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary. Endocr Pract. 2017;23(4):479-97. [Crossref]  [PubMed] 
  4. Benjamin EJ, Balha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603. [Crossref] 
  5. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis. 1998;141(Suppl 1):S57-S62. [Crossref] 
  6. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. [Crossref]  [PubMed]  [PMC] 
  7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 partipants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. [Crossref] 
  8. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45. [Crossref]  [PubMed] 
  9. Sozmen K, Unal B, Sakarya S, Dinc G, Yardim N, Keskinkilic B, et al. Determinants of prevalence, awareness, treatment and control of LDL-C in Turkey. Anatol J Cardiol. 2016;16(6):370-84. [Crossref]  [PMC] 
  10. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon Lipid Study. Endocrine. 2008;34(1-3):36-51. [Crossref]  [PubMed] 
  11. Unal B, Sozmen K, Ucku R, Ergor G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anadolu Kardiyol Derg. 2013;13(1):9-17. [Crossref] 
  12. Oner S, Balcilar M, Erguder T. Turkiye Hanehalki Saglik Arastirmasi: Bulasici Olmayan Hastaliklarin Prevalansi 2017 (STEPS). Ankara: Dunya Saglik Orgutu Turkiye Ofisi; 2018. p.109.
  13. Zhang L, Qiao Q, Dong Y. Ethnic difference in lipid profiles. Dyslipidemia. In: Kelishadi R, ed. From Prevention to Treatment. 2012. Erisim tarihi: 31 Aralik 2018. Available from: http://www.intechopen.com/books/dyslipidemia-from-prevention-to-treatment/ethnic-differences-in-lipid-profiles. [Crossref] 
  14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. [Crossref]  [PubMed] 
  15. Bays HE, Chapman RH, Fox KM, Grandy S; SHIELD Study Group. Comparison of self-reported survey (SHIELD) versus NHANES data estimating prevalence of dyslipidemia. Curr Med Res Opin. 2008;24(4):1179-86. [Crossref]  [PubMed] 
  16. Steinhagen-Thiessen E, Bramlage P, Losch C, Hauner H, Schunkert H, Vogt A, et al. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol. 2008;7:31. [Crossref]  [PubMed]  [PMC] 
  17. Simao AF, Precoma DB, Andrade JP, Correa Filho H, Saraiva JF, Oliveira GM; Brazilian Society of Cardiology. [I cardiovascular prevention guideline of the Brazilian Society of Cardiology - executive summary]. Arq Bras Cardiol. 2014;102(5):420-31.
  18. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. [Crossref] 
  19. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systemic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 miilion participants. Lancet. 2011;377(9765):578-86. [Crossref] 
  20. Giampaoli S. CUORE: a sustainable cardiovascular disease prevention strategy. Eur J Cardiovasc Prev Rehabil. 2007;14(2):161-2. [Crossref]  [PubMed] 
  21. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European SoGAety of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(Suppl 1):S1-S44.
  22. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1- executive summary. J Clin Lipidol. 2014;8(5):473-88. [Crossref]  [PubMed] 
  23. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. J Clin Lipidol. 2014;8(1):29-60.
  24. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. [Crossref]  [PubMed] 
  25. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoproteins(a), apolipoproteins A-1 and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-13. [Crossref]  [PubMed] 
  26. Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36(4):839-59.
  27. Onat A. Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anadolu Kardiyol Derg. 2004;4(3):236-45.
  28. Mahley RW, Mahley LL, Bersot TP, Pepin GM, Palaoglu KE. The Turkish lipid problem: low levels of high density lipoproteins. Turk J Endocr Metab. 2002;6(1):1-12.
  29. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206-16. [Crossref]  [PubMed] 
  30. Kayikcioglu M, Tokgozoglu L, Kilickap M, Goksuluk H, Karaaslan D, Ozer N, et al. [Data on prevalence of dsylipidemia and lipid values in Turkey: systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors]. Turk Kardiyol Dern Ars. 2018;46(7):556-74.
  31. Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med. 2004:164(2):181-8. [Crossref]  [PubMed] 
  32. Jaffer FA, O'Donnell CJ, Larson MG, Chan SK, Kissinger KV, Kupka MJ, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Biol. 2002;22(5):849-54. [Crossref]  [PubMed] 
  33. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet. 2001;357(9256):577-81. [Crossref] 
  34. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055-60. [Crossref]  [PubMed] 
  35. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485-94.
  36. Viviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIME 22 substudy. J Am Coll Cardiol. 2005;46(8):1411-6. [Crossref]  [PubMed] 
  37. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids Health Dis. 2014;13:183. [Crossref]  [PubMed]  [PMC] 
  38. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, et al. High-dose atorvastation after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59. [Crossref]  [PubMed] 
  39. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86(3):1046-60. [Crossref]  [PubMed] 
  40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastation in 20,536 high-risk individulas: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. [Crossref] 
  41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastation on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:(14)1001-9. [Crossref]  [PubMed] 
  42. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22. [Crossref]  [PubMed] 
  43. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com